6月10日，Parabilis Medicines盘中上涨49.15%，报29.83美元/股，成交额1.01亿美元。
消息面上，公司当日完成美股IPO并挂牌上市，发行价定为每股20美元，高于此前17-19美元的推介区间，IPO认购需求达可供股份数的约10倍。本次IPO发行3350万股，募资约6.70亿美元；同时再生元制药以每股18美元认购约7500万美元股份，合计筹资近7.45亿美元。
Parabilis Medicines是一家临床阶段生物制药公司，专注于开发用于癌症治疗的工程化肽疗法。公司核心平台Helicon通过稳定化螺旋肽进入细胞内部，靶向传统药物难以覆盖的细胞内癌症驱动靶点。其领先候选药物zolucatetide在硬纤维瘤临床试验中显示100%患者肿瘤缩小，74%达到客观缓解，计划于明年上半年启动3期注册性临床试验。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.